Trending storyPast story
Enveda raises $311M to push nature-derived AI drugs into trials
1 report1 sourceupdated 6 days ago
What happened
Summary
Enveda 完成 3.11 亿美元 E 轮融资，估值 20 亿美元，比一年前翻了一倍。这家公司不做实验室合成，而是用 AI 从植物和微生物里筛候选药物。目前有两个药进了人体试验：一个针对严重皮肤病，另一个帮停用 GLP-1 后维持体重。正文没披露试验处于几期、入组人数和初步数据，所以离验证药效还有距离。如果是真的，这种“从自然界找药+AI 加速”的思...
Coverage
Follow the reports to see the story from different sides.
Sep 24
- TechCrunch · AIEnveda raises $311M to push nature-derived AI drugs into trials
Enveda raised $311M Series E at a $2B valuation. It uses AI to discover drugs from plants and microbes, not lab synthesis. Two candidates are in human trials: one for severe skin conditions, another to maintain weight loss after stopping GLP-1s. The post doesn't specify trial phases or timelines.